EXCLUSIVE: Alzamend Neuro Tells Benzinga 'Safety aspects of AL001 development may qualify for a Section (505)(b)(2) NDA pathway in support of FDA approval'
Portfolio Pulse from Benzinga Newsdesk
Alzamend Neuro has indicated that the safety aspects of its AL001 development may qualify for a Section (505)(b)(2) NDA pathway, which could support FDA approval.
October 02, 2023 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alzamend Neuro's AL001 development may qualify for a Section (505)(b)(2) NDA pathway, potentially aiding FDA approval.
The news that Alzamend Neuro's AL001 development may qualify for a Section (505)(b)(2) NDA pathway is highly relevant and important for the company. This could potentially expedite the FDA approval process for AL001, which would be a significant positive development for the company. As such, this news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100